We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Leading Indian drugmakers Ranbaxy, Cipla, Sun Pharma, Wockhardt and
Nicholas Piramal have blamed worsening first-quarter sales on local taxes, marketing
expenses in the US and the country's new patent law.
Actimis Pharmaceuticals, a startup company dedicated to developing and commercializing
small molecule therapeutics for respiratory and inflammatory diseases, today
announced a $6 million private placement of its Series A stock.
Dishman Pharmaceuticals & Chemicals (DPCL) on Thursday announced about the
execution of various agreements with Arab Company for Drug Industries and Medical
Appliances (ACDIMA), promoted by 18 Arab Nations for economic development of
these nations through setting up of projects in various fields, including manufacturing
of raw materials for pharmaceutical industry with a view to setting up a joint
venture (JV) project initially to manufacture 20 APIs for not only marketing
in the Arab world but also exporting them.
Denmark became the first European country to support the Aeras Global TB Vaccine
Foundation's efforts to develop a safe, effective tuberculosis vaccine with
announcements of new financial commitments and scientific partnerships.
Bentley Pharmaceuticals, a technology-based specialty pharmaceutical and drug
delivery company with a growing branded and generic product line in Europe,
announced that one of its Spanish subsidiaries, Laboratorios Davur, has received
approval to market 1 mg, 3 mg and 6 mg generic dosage versions of risperidone
in Spain.
Ranbaxy Laboratories, the leading Indian pharmaceutical giant, suffered heavy
setback during the first quarter ended March 2005 basically due to implementation
of VAT, USA Quinapril litigation and the phasing of European first day launches.
Elixir Pharmaceuticals announced
an exclusive license agreement with Bristol-Myers Squibb Company for worldwide
development and commercialization rights to Bristol-Myers Squibb's growth hormone
secretagogue (GHS), BMS-604992, and five related compounds.
South African HIV/AIDS activist groups have alleged that the government
has broken its own pledges on bringing treatment to the country's estimated
9.1mn sufferers.
The Central American Free Trade Agreement, due to be enacted by the
US Congress next month, has been condemned by US-based HIV/AIDS activist group
the AIDS Healthcare Foundation.